(Reuters) - Novavax Inc said on Tuesday it has set up a team of company veterans as it seeks U.S. regulatory approval for its seasonal influenza vaccine and to help develop a combined influenza/COVID-19 vaccine for use after the pandemic.
The flu vaccine, NanoFlu, met the primary and secondary goals in late-stage comparison study with Sanofi’s influenza vaccine Fluzone Quadrivalent earlier in the year.
Novavax is among global drugmakers racing to develop a vaccine for COVID-19 and last month started a late-stage trial of its experimental vaccine, NVX‑CoV2373, in the United Kingdom.
NVX‑CoV2373 is also being tested in two ongoing mid-stage trials that began in August.
Reporting By Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila
Our Standards: The Thomson Reuters Trust Principles.